8-K: Horizon Technology Finance Reports Q4 and Full Year 2024 Results; NII Covers Distributions

Sentiment:

Earnings Release


Horizon Technology Finance announced its Q4 and full year 2024 financial results, with net investment income covering regular monthly distributions for the year and a debt portfolio yield of 14.9%.

Worse than expectedNet investment income decreased compared to the prior year.NAV per share decreased compared to the prior year.

Summary

  • Horizon Technology Finance Corporation announced its financial results for the fourth quarter and full year ended December 31, 2024.
  • For Q4 2024, net investment income (NII) was $10.4 million, or $0.27 per share, compared to $15.0 million, or $0.45 per share, for the prior-year period.
  • The total investment portfolio was $697.9 million as of December 31, 2024, and net asset value was $336.2 million, or $8.43 per share.
  • The annualized portfolio yield on debt investments was 14.9% for the quarter.
  • Horizon funded seven loans totaling $59.1 million and raised approximately $18.8 million through an at-the-market (ATM) offering program.
  • For the full year 2024, net investment income was $47.8 million, or $1.32 per share, compared to $61.4 million, or $1.98 per share, for the prior year.
  • The company achieved an annual portfolio yield on debt investments of 15.6% for 2024.
  • Horizon funded 25 loans totaling $197.2 million during the year.
  • The company declared regular monthly distributions totaling $0.33 per share through June 2025.
  • As of December 31, 2024, the company had $131.1 million in available liquidity.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While NII and NAV are down, the company is growing its portfolio and covering distributions. The management expresses optimism about future growth and improving credit quality.

Positives

  • Net investment income covered regular monthly distributions for 2024.
  • The company grew the size of its portfolio for the second consecutive quarter.
  • Horizon strengthened its balance sheet by raising approximately $19 million through its ATM program and completing a $20 million convertible notes offering.
  • The company declared monthly distributions totaling $0.33 per share through June 2025.
  • Horizon ended the year with a committed backlog of $207 million.

Negatives

  • Net investment income decreased compared to the prior year, with Q4 2024 NII at $0.27 per share versus $0.45 per share in Q4 2023, and full year 2024 NII at $1.32 per share versus $1.98 per share in 2023.
  • NAV per share decreased to $8.43 as of December 31, 2024, compared to $9.71 as of December 31, 2023.
  • The dollar-weighted annualized yield on average debt investments decreased from 16.8% in Q4 2023 to 14.9% in Q4 2024.
  • Net realized loss on investments increased to $3.2 million in Q4 2024 from $1.2 million in Q4 2023.
  • Net unrealized depreciation on investments was $19.6 million in Q4 2024.

Risks

  • Stressed investments impacted NAV per share in the fourth quarter.
  • There is potential for future loss of principal for loans rated as 2.
  • Loans rated as 1 represent deteriorating credit quality and a high degree of risk of loss of principal.
  • There can be no assurance that any additional lenders will make any commitments under the Key Facility.

Future Outlook

The company expects to grow its portfolio through new, high-quality venture debt investments while continuing to focus on improving its credit quality and seeking to increase its NAV as it progresses through 2025.

Management Comments

  • We grew the size of our portfolio for the second consecutive quarter through a number of new, high-quality loans, while the NII of $0.27 we generated in the quarter contributed to our NII covering our regular monthly distributions for 2024, said Robert D. Pomeroy, Jr., Chairman and Chief Executive Officer of Horizon.
  • Meanwhile, NAV per share was impacted in the fourth quarter by stressed investments, which we continue to actively manage and support in order to maximize their value.

Industry Context

Horizon's focus on venture debt financing for technology, life science, healthcare, and sustainability companies aligns with the growing demand for specialized financing solutions in these sectors.

Comparison to Industry Standards

  • It is difficult to make a direct comparison without knowing the specific composition and risk profile of Horizon's portfolio compared to other BDCs.
  • Companies like Ares Capital (ARCC) and Main Street Capital (MAIN) are larger BDCs with more diversified portfolios, while Horizon focuses on venture debt.
  • Horizon's portfolio yield of 14.9% is relatively high, reflecting the higher risk and potential returns associated with venture debt investments.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Investment Management AgreementStockholders approved a new investment management agreement with Horizon Technology Financial Management LLC, the investment advisor to the Company (HTFM), the terms of which are identical to those contained in the Investment Management Agreement.If and when Wendel Group acquires a controlling interest in Monroe Capital LLC, and indirectly in HTFM.The new investment management agreement will become effective, if and when, Wendel Group (Euronext: MF:FP) (Wendel) acquires a controlling interest in Monroe Capital LLC (Monroe Capital), and indirectly in HTFM.

Stakeholder Impact

  • Shareholders will receive monthly distributions of $0.11 per share through June 2025.
  • The company's focus on venture capital-backed companies in technology, life science, healthcare, and sustainability industries supports innovation and growth in these sectors.
  • Employees are likely to be impacted by the company's efforts to manage stressed investments and improve credit quality.

Next Steps

  • The company will host a conference call on March 5, 2025, to discuss its latest corporate developments and financial results.
  • Horizon will continue to focus on improving its credit quality and seeking to increase its NAV.
  • The company will continue to actively manage and support stressed investments in order to maximize their value.

Key Dates

DateDescription
November 15, 2024Reinvestment period of the 2022 Notes ended
December 31, 2024End of fourth quarter and full year 2024
January 2, 2025Funded a $20.0 million debt investment to Pivot Bio, Inc.
January 7, 2025Pivot Bio repaid $20.0 million under the revolving commitment.
January 9, 2025Purchased a debt investment to Hound Labs, Inc. for $0.5 million.
January 10, 2025Funded a $6.0 million debt investment to HappyCo, Inc.
January 15, 2025Funded a $2.0 million equity investment to Swift Health Systems, Inc.
January 31, 2025Funded a $2.5 million debt investment to BriteCore Holdings, Inc.
February 11-25, 2025Funded a $0.4 million debt investment to Better Place Forests Co.
February 21, 2025Stockholders approved a new investment management agreement with HTFM.
February 25, 2025Funded a $25.5 million debt investment to Castle Creek Biosciences, Inc.
February 27, 2025Funded a $10.0 million debt investment to Long Grove Pharmaceutical, LLC.
February 28, 2025Funded a $15.0 million debt investment to MML US, Inc. dba Mainstay Medical; Board declared monthly distributions of $0.11 per share for April, May, and June 2025.
March 4, 2025Candesant Biomedical, Inc. prepaid its outstanding principal balance of $10.0 million on its venture loan.
March 5, 2025Company will host a conference call to discuss its latest corporate developments and financial results.
April 17, 2025Convertible Notes may be converted into common stock by the holders.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.